Tesamorelin & Ipamorelin Blend (8mg)
$109.00 $90.00
Tesamorelin & Ipamorelin Product Information
This product is an 8mg blend of two high-purity peptides: Tesamorelin (6mg) and Ipamorelin (2mg). It is provided in a lyophilized powder form with a certified purity of >99%, making it suitable for research applications. The SKU is TESA-IPA-8MG.
Pricing and Discounts
5-8 units: A 5% discount is applied, with a price of $85.50 per unit.
9+ units: A 10% discount is applied, with a price of $81.00 per unit.
We also offer FREE shipping on all orders over $200.
The Tesamorelin & Ipamorelin blend combines two synthetic peptides, Tesamorelin and Ipamorelin, that are being researched for their potential to stimulate the growth hormone (GH) axis through distinct mechanisms. This dual-action approach may lead to a synergistic release of endogenous growth hormone.
1. Mechanisms of Action 🧪
The potential synergy of this blend stems from the different pathways each peptide targets:
Tesamorelin: As an analog of GHRH, Tesamorelin is thought to bind to and activate the GHRH receptors located on somatotroph cells in the pituitary gland. This action is believed to trigger the synthesis and secretion of endogenous GH in a pulsatile (burst-like) manner.
Ipamorelin: This peptide is a selective growth hormone secretagogue receptor (GHSR) agonist. It is believed to activate the GHSR in the hypothalamus and pituitary, leading to the release of GH. Unlike some other GH-releasing compounds, Ipamorelin appears to be highly specific to GHSR, potentially without affecting other hormones like cortisol or prolactin.
Synergistic Effect: By activating both the GHRH and ghrelin pathways, the blend may amplify the overall GH response, potentially leading to more robust and sustained effects on metabolism, body composition, and other functions.
Licensed by Google
2. Research and Clinical Studies 🔬
While there are no publicly available clinical studies on this specific blend, research on the individual peptides offers insight into their potential actions.
Endocrine and Metabolic Effects
Growth Hormone: Studies on Tesamorelin alone have shown a potential 69% increase in total GH levels, while Ipamorelin has been associated with a potential GH elevation of over 60-fold. The blend is hypothesized to combine these effects for enhanced results.
Lipodystrophy: Tesamorelin has been researched for its potential to reduce visceral adipose tissue (VAT), and Ipamorelin is also thought to influence fat metabolism. The combination may offer a synergistic approach to reducing VAT and improving related metabolic markers like lipid profiles.
Type 2 Diabetes: Both peptides have shown promise in preclinical studies for improving glucose metabolism and insulin sensitivity. Their combined use is being explored for potential complementary effects on blood sugar control.
Anabolic and Other Effects
Muscle Density: Tesamorelin has been linked to potential improvements in muscle density and size, particularly in specific muscle groups. Ipamorelin is also being explored for similar effects, with some studies suggesting a potential increase in muscle fiber size and overall muscle strength.
Bone Density: Research on Ipamorelin has hinted at a potential positive impact on bone health, possibly by stimulating bone formation and increasing bone mineral content.
Appetite and Digestion: Due to its interaction with ghrelin receptors, Ipamorelin is being researched for its effects on appetite, which may lead to weight gain, and its potential to expedite gastric emptying and enhance gastric muscle contractility.
3. Product Information 🧬
PeptideMolecular FormulaMolecular WeightTesamorelinC221H366N72O67S5136 g/molIpamorelinC38H49N9O5711.8 g/mol
Export to Sheets
Important Notice: The Tesamorelin & Ipamorelin blend is available for research and laboratory purposes only. It is not intended for human or veterinary use. All information provided is for educational and scientific reference only and has not been evaluated by the FDA or any medical regulatory body.